Drugs / MFEz T lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01212887 | Aug 2007 → Apr 2010 | breast cancer, cancer of unknown primary site, colorectal cancer, gastric cancer +3 | Cancer Research UK | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MFEz T lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01212887 ↗ |
| Action | Deplete | “Giving specially treated T cells together with cyclophosphamide, fludarabine phosphate, and aldesleukin may kill more tumor cells.” NCT01212887 ↗ |
| Modality | Cell therapy | “MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes” NCT01212887 ↗ |
| Route | Intravenous | “They receive MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes IV over 30 minutes on day 0.” NCT01212887 ↗ |